Stockscreener 앱 받기
3.985
0.64%
0.055
전일 마감가:
$3.93
열려 있는:
$3.855
하루 거래량:
2.54M
Relative Volume:
0.69
시가총액:
$656.35M
수익:
$101.21M
순이익/손실:
$-569.00K
주가수익비율:
-199.25
EPS:
-0.02
순현금흐름:
$-56.88M
1주 성능:
+19.13%
1개월 성능:
+19.85%
6개월 성능:
+393.14%
1년 성능:
+291.58%
1일 변동 폭
$3.71
$4.18
1주일 범위
$3.22
$4.18
52주 변동 폭
$0.40
$4.18
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
명칭
Cytomx Therapeutics Inc
전화
650.515.3185
주소
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
CTMX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CTMX
Cytomx Therapeutics Inc
|
3.98 | 648.11M | 101.21M | -569.00K | -56.88M | -0.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
428.08 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
631.04 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
426.73 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
840.57 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
184.16 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-09-17 | 재개 | Barclays | Overweight |
| 2025-07-31 | 개시 | Oppenheimer | Outperform |
| 2025-05-15 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-04-14 | 재개 | Piper Sandler | Overweight |
| 2024-05-28 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-05-09 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2024-05-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-04-22 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2022-11-14 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-07-07 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-07 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-07-07 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-07-07 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2022-06-24 | 개시 | BMO Capital Markets | Outperform |
| 2022-01-18 | 업그레이드 | Barclays | Underweight → Overweight |
| 2021-11-15 | 개시 | BTIG Research | Buy |
| 2021-05-28 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2021-03-29 | 개시 | JP Morgan | Overweight |
| 2021-03-23 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-09-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2020-06-01 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-05-14 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-24 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2020-03-04 | 개시 | Barclays | Equal Weight |
| 2019-11-20 | 개시 | Guggenheim | Buy |
| 2019-11-11 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-06-13 | 개시 | Mizuho | Buy |
| 2019-05-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-03-11 | 개시 | Barclays | Overweight |
| 2018-11-26 | 개시 | Piper Jaffray | Overweight |
| 2018-10-15 | 개시 | Goldman | Neutral |
| 2018-09-13 | 개시 | H.C. Wainwright | Buy |
| 2018-06-01 | 개시 | SunTrust | Buy |
| 2018-01-05 | 개시 | Citigroup | Buy |
| 2017-09-08 | 개시 | Wedbush | Outperform |
| 2017-03-27 | 개시 | H.C. Wainwright | Buy |
| 2017-03-02 | 개시 | Instinet | Buy |
| 2017-01-03 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2015-11-02 | 개시 | Oppenheimer | Outperform |
모두보기
Cytomx Therapeutics Inc 주식(CTMX)의 최신 뉴스
CytomX stock rises after initial data shows CX-801 working as designed By Investing.com - Investing.com South Africa
CytomX Therapeutics, Inc. to Present CX-801 Phase 1 Monotherapy Biomarker Data at the Society for Immunotherapy of Cancer Annual Meeting - MarketScreener
CytomX reports tumor-selective activation in melanoma treatment trial - Investing.com
CytomX Therapeutics Announces Phase 1 Data for CX-801 Highlighting Tumor-Selective Interferon Signaling in Advanced Melanoma Patients - Quiver Quantitative
CytomX (NASDAQ: CTMX) to present CX-801 Phase 1 biomarker data on interferon signaling - Stock Titan
What dividend safety rating applies to CytomX Therapeutics Inc. (6C1) stockJuly 2025 Decliners & Verified Swing Trading Watchlists - newser.com
CytomX Therapeutics (NASDAQ:CTMX) Sets New 52-Week HighStill a Buy? - MarketBeat
Is CytomX Therapeutics Inc. (6C1) stock attractive post correctionQuarterly Portfolio Report & Smart Money Movement Alerts - newser.com
How CytomX Therapeutics Inc. stock compares to market leadersWeekly Stock Analysis & AI Enhanced Market Trend Forecasts - newser.com
What insider purchases suggest about CytomX Therapeutics Inc. (6C1) stockGlobal Markets & Reliable Intraday Trade Plans - newser.com
Can CytomX Therapeutics Inc. stock reach $100 price targetEarnings Performance Report & Safe Capital Growth Trade Ideas - newser.com
Will CytomX Therapeutics Inc. (6C1) stock outperform Dow Jones2025 Historical Comparison & Growth Focused Investment Plans - newser.com
Visual analytics tools that track CytomX Therapeutics Inc. performanceJuly 2025 Decliners & Advanced Technical Signal Analysis - newser.com
Why CytomX Therapeutics Inc. (6C1) stock is a strong buy call2025 Trading Recap & Fast Gaining Stock Strategy Reports - newser.com
How to integrate CytomX Therapeutics Inc. into portfolio analysis toolsJuly 2025 Review & Weekly Watchlist for Consistent Profits - newser.com
What earnings margins imply for CytomX Therapeutics Inc. (6C1) stock2025 Market Outlook & Smart Swing Trading Alerts - newser.com
Will CytomX Therapeutics Inc. stock reach Wall Street targetsJuly 2025 PreEarnings & Weekly Breakout Opportunity Watchlist - newser.com
What analyst consensus implies for CytomX Therapeutics Inc. (6C1) stockJuly 2025 PostEarnings & Free AI Powered Buy and Sell Recommendations - newser.com
Is CytomX Therapeutics Inc. (6C1) stock a buy on weakness2025 Biggest Moves & Stock Portfolio Risk Control - newser.com
Why retail traders accumulate CytomX Therapeutics Inc. (6C1) stockAnalyst Upgrade & Accurate Intraday Trade Tips - newser.com
Using data filters to optimize entry into CytomX Therapeutics Inc.Market Trend Report & Reliable Intraday Trade Plans - newser.com
How CytomX Therapeutics Inc. stock performs in rate cut cyclesJuly 2025 Update & Short-Term Trading Opportunity Alerts - newser.com
Published on: 2025-11-02 12:38:04 - newser.com
Key metrics from CytomX Therapeutics Inc.’s quarterly data2025 Earnings Surprises & Technical Buy Zone Confirmations - newser.com
Using Ichimoku Cloud for CytomX Therapeutics Inc. technicalsQuarterly Portfolio Report & Long-Term Capital Growth Strategies - newser.com
How CytomX Therapeutics Inc. stock reacts to oil pricesJuly 2025 Short Interest & Weekly Return Optimization Alerts - newser.com
Why analysts maintain buy rating on CytomX Therapeutics Inc. (6C1) stockShort Setup & Real-Time Volume Triggers - newser.com
What drives CytomX Therapeutics Inc 6C1 stock priceMarket Sentiment Report & Trusted Financial Advisors at No Cost - earlytimes.in
Is CytomX Therapeutics Inc. (6C1) stock considered safe havenTrade Analysis Summary & Free Technical Pattern Based Buy Signals - newser.com
CytomX Therapeutics (CTMX) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Building trade automation scripts for CytomX Therapeutics Inc.2025 Macro Impact & AI Driven Stock Movement Reports - newser.com
Cytomx Therapeutics Inc (CTMX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.32%
0.35%
자본화:
|
볼륨(24시간):